Ask AI
ProCE Banner Activity

Experts Discuss the Use of Immunotherapy in HNSCC

Clinical Thought

In this commentary, expert faculty explore current recommendations and evolving strategies in the use of immune checkpoint inhibitor therapy for head and neck squamous cell carcinoma (HNSCC) across the disease continuum.

Released: July 16, 2025

Expiration: January 15, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Coherus BioSciences, Inc. and Merck Sharp & Dohme Corp.

Coherus BioSciences, Inc.

Merck Sharp & Dohme Corp.

Disclosure

Primary Author

Barbara Burtness, MD: consultant/advisor/speaker: AstraZeneca, Genmab, GlaxoSmithKline, Merck, Merck KgA, IO Biotech, Takeda; researcher (paid to institution): Daiichi Sankyo, GlaxoSmithKline, IO Biotech, Merck, Merck KgA; data safety and monitoring board: ALX Oncology, Merus.

Robert Haddad, MD: consultant/advisor/speaker: AstraZeneca, Aveo, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Genmab, GlaxoSmithKline, Johnson & Johnson, Merck, PDS Biotech, RAPT, Takeda; data and safety monitoring board: Hookipa, Nanobiotix; researcher (paid to institution): AstraZeneca, Aveo, EMD Serono, GlaxoSmithKline, Incyte, Kura, Merck, Merus.

Cristina Rodriguez, MD: researcher (paid to institution): Adagene, Bristol Myers Squibb, Coherus, Cue Biopharma, Lilly, Merck, Onco4, Rgenta, Sanofi, Seagen/Pfizer; consultant/advisor/speaker: Adaptimmune, Eisai, Vaccitech; data and safety monitoring board: Pionyr.